Product Center
Ab&B Bio-Exhibition Wrapped Up Successfully
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-04-23
- Views:
(Summary description)From April 20 to 21, 2024, the National Conference on Vaccines and Health was held in Xiongan, Hebei Province, with the theme of “Standardize, Expand, Innovate – Promoting the Construction of a Healthy China with High-Quality Immunization Services”, focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services and facilitating discussions on optimization strategies. The conference focused on the scientific and practical issues involved in the high-quality development of vaccine immunization services, exchanged research results, shared practical experiences, and discussed optimization strategies.
Ab&B Bio-Exhibition Wrapped Up Successfully
(Summary description)From April 20 to 21, 2024, the National Conference on Vaccines and Health was held in Xiongan, Hebei Province, with the theme of “Standardize, Expand, Innovate – Promoting the Construction of a Healthy China with High-Quality Immunization Services”, focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services and facilitating discussions on optimization strategies. The conference focused on the scientific and practical issues involved in the high-quality development of vaccine immunization services, exchanged research results, shared practical experiences, and discussed optimization strategies.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-04-23 10:20
- Views:
From April 20 to 21, 2024, the National Conference on Vaccines and Health was held in Xiongan, Hebei Province, with the theme of “Standardize, Expand, Innovate – Promoting the Construction of a Healthy China with High-Quality Immunization Services”, focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services and facilitating discussions on optimization strategies. The conference focused on the scientific and practical issues involved in the high-quality development of vaccine immunization services, exchanged research results, shared practical experiences, and discussed optimization strategies.

Ab&B Bio-Tech Co., Ltd. (JS) participated in the exhibition with China’s first quadrivalent influenza virus subunit vaccine (HRK-X®). During the meeting, the staff provided a detailed introduction to the company and its products for experts and scholars from medical and healthcare institutions, research institutes, and colleges and universities across China, highlighting the characteristics of the subunit influenza vaccine, which extracts only the effective antigens, hemagglutinin and neuraminidase, through the structure of the influenza virus, and garnered widespread attention and positive feedback.

This conference featured a number of parallel sessions, such as “50 Years of Global EPI – The Road to China”, in which more than 160 renowned experts from China shared their academic achievements on hot topics in the fields of vaccine research and development, vaccination-based prevention, and disease prevention and control. Among them, in the session report on “Progress and Application of Vaccine Clinical Trials”, Director Pan Hongxing from the Vaccine Clinical Evaluation Institute of Jiangsu CDC presented on the “Progress of Clinical Evaluation of New Domestic Influenza Vaccines”, covering the current status of influenza vaccine application in China and globally, interim safety data from the Phase III clinical study of the new domestic quadrivalent subunit influenza vaccine, and related scientific research projects of the National Center for Evaluation.

Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us